Canaccord raised the firm’s price target on Stryker (SYK) to $400 from $360 and keeps a Buy rating on the shares. The firm said they delivered an impressive Q3 of 11.9% reported growth, raising the low end of its top and bottom line guidance while citing continued healthy capital demand and procedure volumes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: